COMPOSITION FOR CONTROLLING BLOOD GLUCOSE AND METHOD THEREOF

• US 20090110752A1
• Filed: 02/08/2008
• Published: 04/30/2009
• Est. Priority Date: 10/29/2007
• Status: Abandoned Application

• Current Assignee: National Applied Research Laboratories (Government of The Republic of China), Taipei Medical University WAN Fan Hospital (Government of The Republic of China)
• Original Assignee: National Applied Research Laboratories (Government of The Republic of China), Taipei Medical University WAN Fan Hospital (Government of The Republic of China)
• Inventors: Shang, Huey-Fang, Hsu, Chung-Huei, Lin, Yung-Sheng, Leung, Ting-Kai
• Application Number:
  US12/028,044
• Publication Number:
  US 20090110752A1
• Time in Patent Office: Days
• US Class Current: 424/647
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/08 Oxides; Hydroxides
• CPC Class Codes: A61K 33/10 Carbonates; Bicarbonates
• CPC Class Codes: A61K 33/26 Iron; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61N 2005/066 far infrared
• CPC Class Codes: A61N 5/0613 Apparatus adapted for a specific treatment
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A composition for controlling a blood glucose and a method thereof are provided. The composition comprises a far-infrared ray releasing substance, wherein the composition reduces the blood glucose of a subject via an irradiation of the far-infrared ray releasing substance. In another aspect, the method comprises the steps of providing a far-infrared ray releasing substance having an oxide mineral as a main component, and disposing the far-infrared ray releasing substance in a place close to a subject in an appropriate distance, wherein the subject has an insulin resistance and the appropriate distance is within an irradiation range of the far infrared ray.

Claims

1. A pharmaceutical composition for controlling a blood glucose of a subject having an insulin resistance, comprising:

a far-infrared ray releasing substance including an 80%-99.9% oxide mineral in weight, wherein the oxide mineral comprises a 60-95% aluminum oxide in weight.

2. A pharmaceutical composition as claimed in claim 1, further comprising a pharmaceutically acceptable carrier.

3. A pharmaceutical composition as claimed in claim 1, wherein the insulin resistance comprises one selected from a group consisting of a type II diabetes, a post-surgical syndrome, a serious illness, a burn injury, a post-traumatic syndrome, a related complication and a combination thereof.

4. A pharmaceutical composition as claimed in claim 1, wherein the far-infrared ray releasing substance irradiates a far-infrared ray with an emissivity over 0.9 at a wavelength in a range of 6-14 μ

m.

5. A pharmaceutical composition as claimed in claim 1, wherein the far-infrared ray releasing substance reduces the blood glucose at room temperature.

6. A pharmaceutical composition as claimed in claim 1, wherein the far-infrared ray releasing substance further comprises a 1-20% ferric oxide, a 1-10% magnesium oxide and a 1-30% calcium carbonate in weight.

7. A composition for controlling a blood glucose of a subject, comprising:

a far-infrared ray releasing substance,

wherein the composition reduces the blood glucose of the subject via an irradiation of the far-infrared ray releasing substance.

8. A composition as claimed in claim 7, wherein the subject has an insulin resistance.

9. A composition as claimed in claim 7, wherein the far-infrared ray releasing substance comprises an oxide mineral.

10. A composition as claimed in claim 9, wherein the oxide mineral comprises an aluminum oxide.

11. A composition as claimed in claim 7, being used as a pharmaceutical composition.

12. A composition as claimed in claim 11, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

13. A composition as claimed in claim 7, further comprising a base material mixed with the far-infrared releasing substance.

14. A composition as claimed in claim 13, wherein the base material is at least one selected from a group consisting of a metal, a glass, a ceramic and a polymer.

15. A method for controlling a blood glucose, comprising the steps of:

providing a far-infrared ray releasing substance; and

disposing the far-infrared ray releasing substance in a place close to a subject in an appropriate distance, wherein the subject has an insulin resistance and the appropriate distance is within an irradiation range of the far infrared ray.

16. A method as claimed in claim 15, wherein the far-infrared ray releasing substance irradiates the far-infrared ray with an emissivity over 0.9 at a wavelength in a range of 6-14 μ

m, and reduces the blood glucose of the subject via the far-infrared ray irradiation.

17. A method as claimed in claim 15, wherein the far-infrared ray releasing substance comprises an oxide mineral.

18. A method as claimed in claim 17, wherein the oxide mineral comprises an aluminum oxide.

19. A method as claimed in claim 18, wherein the far-infrared ray releasing substance further comprises a 1-20% ferric oxide, a 1-10% magnesium oxide and a 1-30% calcium carbonate in weight.

20. A method as claimed in claim 15, wherein the insulin resistance comprises one selected from a group consisting of a type II diabetes, a post-surgical syndrome, a serious illness, a burn injury, a post-traumatic syndrome, a related complication and a combination thereof.